Pacira BioSciences, Inc. PCRX
Pacira BioSciences, Inc. (Nasdaq: PCRX) is a pain/anesthesia drug developer. Its lead program, EXPAREL (bupivacaine liposome injectable suspension), is in Phase 2 for postsurgical local and regional analgesia. Its next catalyst on record is EXPAREL (LG Chem partnership): LG Chem to file for marketing authorization in Thailand (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EXPAREL (LG Chem partnership) — LG Chem to file for marketing authorization in Thailand (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EXPAREL | postsurgical analgesia (pediatric <6 years registration program ongoing) | small molecule | Approved |
| ZILRETTA | OA knee pain (approved); OA shoulder pain Phase 3 label expansion | small molecule | Approved |
| PCRX-201 (enekinragene inzadenovec) | knee osteoarthritis (HCAd gene therapy, Phase 2 ASCEND, RMAT) | gene therapy | Phase 2 |
| PCRX-2002 (long-acting ropivacaine hydrogel, in-licensed from AmacaThera) | postsurgical pain | small molecule | Phase 1 |
| PCRX-1002 | dry eye disease | gene therapy | Pre-clinical |
| PCRX-1003 | degenerative disc disease | gene therapy | Pre-clinical |
| PCRX-1001 | canine osteoarthritis | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 pain/anesthesia companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.